251 related articles for article (PubMed ID: 21924904)
1. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
[TBL] [Abstract][Full Text] [Related]
2. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
4. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
6. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
7. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
9. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
10. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
11. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
[TBL] [Abstract][Full Text] [Related]
12. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
13. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
14. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Sagara Y; Kosha S; Baba S; Dokiya F; Tamada S; Sagara Y; Matsuyama Y; Ohi Y; Ando M; Rai Y; Sagara Y; Douchi T
Breast Cancer; 2010 Jul; 17(3):212-7. PubMed ID: 19526308
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
16. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
17. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
[TBL] [Abstract][Full Text] [Related]
18. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
20. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]